DC Global Ventures is an SEC-registered investment adviser based in Menlo Park, CA that reports managing 1 hedge fund on Form ADV. It reports $2.7 billion in regulatory assets under management. Its private funds, of all types, hold $2.7 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +5.5% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +81.9% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $2.7 billionForm ADV Item 5.F
- Gross assets of private funds
- $2.7 billionAll private fund types, Form ADV
- Hedge funds managed
- 18 private funds in total
- Employees
- 23Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 293073
- Latest Form ADV
- 03/31/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +12.9% | +14.8% |
| Q1 2026 | -6.6% | -4.6% |
| Q4 2025 | +35.4% | +2.4% |
| Q3 2025 | +47.7% | +7.8% |
| Q2 2025 | +21.0% | +10.4% |
| Q1 2025 | -25.8% | -4.5% |
| Q4 2024 | -13.7% | +2.1% |
| Q3 2024 | +11.3% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Largest disclosed holdings
- CG Oncology Inc$452.7 million
- Nuvation Bio Inc$147.4 million
- Aardvark Therapeutics Inc$22.6 million
- Aclaris Therapeutics Inc$21.4 million
- Upstream Bio Inc$18.9 million
- Arcus Biosciences Inc$14.3 million
- Quillium Inc$14.2 million
- Revolution Medicines Inc$9.9 million
- Lyell Immunopharma Inc$9.7 million
- Beyondspring Inc$6.7 million
As of 2026-06-30, from 13F filing by Decheng Capital LLC.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. HedgeMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures